Close
  Indian J Med Microbiol
 

Figure 3: Bioluminescence of BEL-7402 tumor xenografts. (A-B) Color-coded bioluminescence maps of the animals in different groups before and 7 d after treatment for each animal in each treatment group. The left column in each panel shows bioluminescence before treatment, and the right column shows bioluminescence 7 d after treatment completion. A: recombinant human calcineurin B (rhCNB) high (H-rhCNB), medium (M-rhCNB), low (L-rhCNB), and dose-escalation group (DE-rhCNB), respectively; B: cisplatin positive control, hydroxycamptothecin (HCPT) positive control, recombinant human interleukin-2 (rhIL-2) positive control, and vehicle (VC) control group, respectively.

Figure 3: Bioluminescence of BEL-7402 tumor xenografts. (A-B) Color-coded bioluminescence maps of the animals in different groups before and 7 d after treatment for each animal in each treatment group. The left column in each panel shows bioluminescence before treatment, and the right column shows bioluminescence 7 d after treatment completion. A: recombinant human calcineurin B (rhCNB) high (H-rhCNB), medium (M-rhCNB), low (L-rhCNB), and dose-escalation group (DE-rhCNB), respectively; B: cisplatin positive control, hydroxycamptothecin (HCPT) positive control, recombinant human interleukin-2 (rhIL-2) positive control, and vehicle (VC) control group, respectively.